DK0774962T3 - Anvendelse af DHA i behandlingen af ordblindhed - Google Patents

Anvendelse af DHA i behandlingen af ordblindhed

Info

Publication number
DK0774962T3
DK0774962T3 DK96919911T DK96919911T DK0774962T3 DK 0774962 T3 DK0774962 T3 DK 0774962T3 DK 96919911 T DK96919911 T DK 96919911T DK 96919911 T DK96919911 T DK 96919911T DK 0774962 T3 DK0774962 T3 DK 0774962T3
Authority
DK
Denmark
Prior art keywords
pct
dyslexia
dha
treatment
sec
Prior art date
Application number
DK96919911T
Other languages
Danish (da)
English (en)
Inventor
Barbara Jacqueline Stordy
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia Nv filed Critical Nutricia Nv
Application granted granted Critical
Publication of DK0774962T3 publication Critical patent/DK0774962T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96919911T 1995-05-25 1996-05-24 Anvendelse af DHA i behandlingen af ordblindhed DK0774962T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9510636.5A GB9510636D0 (en) 1995-05-25 1995-05-25 Fatty acid treatment
PCT/GB1996/001265 WO1996037200A1 (en) 1995-05-25 1996-05-24 Use of dha as a pharmaceutical composition

Publications (1)

Publication Number Publication Date
DK0774962T3 true DK0774962T3 (da) 2004-08-09

Family

ID=10775045

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96919911T DK0774962T3 (da) 1995-05-25 1996-05-24 Anvendelse af DHA i behandlingen af ordblindhed

Country Status (16)

Country Link
US (1) US6150411A (pt)
EP (1) EP0774962B1 (pt)
JP (1) JPH10503531A (pt)
KR (1) KR970704433A (pt)
AT (1) ATE264676T1 (pt)
AU (1) AU722474B2 (pt)
CA (1) CA2195979A1 (pt)
DE (1) DE69632236T2 (pt)
DK (1) DK0774962T3 (pt)
ES (1) ES2217317T3 (pt)
FI (1) FI970298L (pt)
GB (1) GB9510636D0 (pt)
NO (1) NO970317L (pt)
PT (1) PT774962E (pt)
WO (1) WO1996037200A1 (pt)
ZA (1) ZA964215B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361066T1 (de) * 1998-10-15 2007-05-15 Dsm Ip Assets Bv Polyungesättigen fettsäuren nährungsergänzung
KR100341109B1 (ko) * 1999-03-10 2002-06-20 이인수 인식력 및 기억력 증강용 식이 조성물
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6258846B1 (en) * 1999-06-01 2001-07-10 Drugtech Corporation Nutritional supplements
GB9918023D0 (en) 1999-07-30 1999-09-29 Unilever Plc Skin care composition
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
DK1417211T3 (da) 2001-07-27 2007-10-08 Neptune Technologies & Bioress Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
EP1713463A4 (en) * 2004-01-19 2009-03-18 Martek Biosciences Corp REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
WO2011050474A1 (en) 2009-10-29 2011-05-05 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
CA3024191C (en) * 2016-06-01 2024-05-28 Nestec S.A. Composition for use in the prophylaxis of allergic disease
EP4440564A4 (en) * 2021-12-02 2026-03-11 Univ California COMPOSITIONS AND METHODS FOR INHIBITING EPILEPTIC SEIZURES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA

Also Published As

Publication number Publication date
HK1012575A1 (en) 1999-08-06
FI970298A0 (fi) 1997-01-24
JPH10503531A (ja) 1998-03-31
EP0774962A1 (en) 1997-05-28
KR970704433A (ko) 1997-09-06
AU722474B2 (en) 2000-08-03
EP0774962B1 (en) 2004-04-21
DE69632236T2 (de) 2005-04-14
AU5827796A (en) 1996-12-11
PT774962E (pt) 2004-09-30
ZA964215B (en) 1996-12-04
FI970298A7 (fi) 1997-01-24
DE69632236D1 (de) 2004-05-27
ES2217317T3 (es) 2004-11-01
US6150411A (en) 2000-11-21
GB9510636D0 (en) 1995-07-19
CA2195979A1 (en) 1996-11-28
WO1996037200A1 (en) 1996-11-28
FI970298L (fi) 1997-01-24
ATE264676T1 (de) 2004-05-15
NO970317D0 (no) 1997-01-24
NO970317L (no) 1997-01-24

Similar Documents

Publication Publication Date Title
DK0774962T3 (da) Anvendelse af DHA i behandlingen af ordblindhed
DE69317433D1 (de) Ungesättigte aliphatische dicarbonsäuren
DK0880350T3 (da) Behandling af dissemineret sklerose
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
EP0850068A4 (en) LIPID EXTRACTS WITH ANTI-INFLAMMATORY ACTIVITY
DE69521512D1 (de) Neues pharmazeutisches präparat zur schmerzbehandlung
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69202019D1 (de) Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS.
KR910007858A (ko) 초기-촉진 및 향상된 진통제로서의 s(+)-이부프로펜-l-아미노산 및 s(+)-이부프로펜-d-아미노산
ATE81453T1 (de) Essentielle fettsaeure enthaltende zusammensetzungen.
GR3023038T3 (en) Use of coconut precursor fatty acid as insect-repellent.
DE69731898D1 (de) Verwendung von Sulphoquinovosyldiacylglycerols zur Behandlung von entzündlichen Hauterkrankungen
ATE220533T1 (de) Kosmetische formulierungen zur verhütung und behandlung von haarausfall
RU95103436A (ru) Способ замедления прогрессирования атеросклероза коронарных артерий с помощью правастатина
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
DE69317716D1 (de) Verwendung von Fettsäuren zur Behandlung von abnormalen Verkalkung des Gewebes
EA200100662A1 (ru) Способ и композиция для поддержания и восстановления целостности кишки
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
UA39179C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, спосіб її одержання та антиаритмічний лікарський засіб
ATE313329T1 (de) Disaccharidderivate zur behandlung von hyperglykämien
DE69328205D1 (de) Rektale Flunisolid-Zubereitung zur Behandlung entzündlicher Darmerkrankungen
ATE218869T1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
UA29506C2 (uk) Лікувально-косметичний засіб "фіто-пелоїд"
DE69319140D1 (de) 4-guanidinobutyramid zur verbesserung des blutkreislaufs
DK0868181T3 (da) Anvendelse af alfa,alfa-diphenyleddikesyre-4-(N-methyl-piperidyl)-estere som spasmoanalgetikum